Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TG1-M8218 | Mouse / Rat | Biotinylated Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Avitag™ | ![]() |
||
TG1-M5218 | Mouse / Rat | Mouse / Rat TGF-Beta 1 / TGFB1 Protein, Tag Free (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
TG1-H8217 | Human | Biotinylated Human TGF-Beta 1 / TGFB1 Protein, Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
TG1-H4212 | Human | ActiveMax® Human TGF-Beta 1 / TGFB1 Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Immobilized Human TGFBR2, Fc Tag (Cat. No. TG2-H5252) at 5 μg/mL (100 μL/well) can bind Biotinylated Human TGF-Beta 1, Avitag (Cat. No. TG1-H8217) with a linear range of 0.1-3 ng/mL (QC tested).
The purity of Mouse / Rat TGFB1, Tag Free (Cat. No. TG1-M5218) is more than 85% and the molecular weight of this protein is around 30-40 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Nicousamide | XLF-III-43 | Phase 2 Clinical | Institue Of Materia Medica Chinese Academy Of Medical Science | Hypertensive nephropathy; Diabetic Nephropathies | Details |
Meflonidone hydrochloride | Phase 1 Clinical | Guangzhou Nanxin Pharma Co Ltd, Central South University | Diabetic Nephropathies | Details | |
Disitertide | P-144; NAFB-001; Peptide-144 | Phase 2 Clinical | Digna Biotech, University Of Navarra | Fibrosis; Scleroderma, Systemic | Details |
STP-707 | STP-707 | Phase 1 Clinical | Suzhou Shengnuo Biological Medicine Technology Co Ltd | Solid tumours; Liver Neoplasms; Liver Cirrhosis; Pulmonary Fibrosis; Cholangitis, Sclerosing | Details |
SRK-181 | SRK-181 | Phase 1 Clinical | Scholar Rock | Neoplasms | Details |
Yinfenidone Hydrochloride | HEC-585; HEC-00000585 | Phase 2 Clinical | Hec Pharm Co Ltd | Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial | Details |
Vactosertib | EW-7197; NOV-1301; TEW-7197 | Phase 2 Clinical | Medpacto | Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Myelodysplastic Syndromes; Urologic Neoplasms; Colorectal Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung | Details |
Fluorofenidone | AKF-PD | Phase 2 Clinical | Dierepharma HK Ltd, Hainan Haiyao Co Ltd, Central South University | Liver Cirrhosis; Renal fibrosis | Details |
Livmoniplimab | ABBV151; MGH-8; ARGX-115; AGRX-115 | Phase 1 Clinical | Argenx Se, Abbvie Inc | Solid tumours | Details |
PXS-64 | PXS-64 | Phase 1 Clinical | Pharmaxis | Multiple Sclerosis; Pulmonary Fibrosis | Details |
STP-705 | STP-705; STP-705LV; STP-705L; STP-705LU | Phase 2 Clinical | Suzhou Shengnuo Biological Medicine Technology Co Ltd, Sirnaomics | Liver Neoplasms; Bowen's Disease; Carcinoma, Basal Cell; Cholangiocarcinoma; Carcinoma, Squamous Cell; Keloid; Cicatrix, Hypertrophic; Carcinoma, Hepatocellular | Details |
NIS-793(Novartis Pharma) | NIS-793 | Phase 3 Clinical | Novartis Pharma Ag | Liver Neoplasms; Kidney Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Breast Neoplasms; Colorectal Neoplasms; Primary Myelofibrosis; Carcinoma, Pancreatic Ductal; Lung Neoplasms | Details |
YL-13027 | YL-13027 | Phase 1 Clinical | Shanghai Yingli Pharmaceutical Co Ltd | Solid tumours | Details |
NNC-0361-0041 | NNC0361-0041; NNC-0361-0041 | Phase 1 Clinical | Novo Nordisk A/S | Diabetes Mellitus, Type 1 | Details |
Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.